Surrozen (SRZN) announced that the company will focus its Wnt biology expertise and Wnt signal modulation antibody technologies on its ...
Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...
All Penny Stocks (English) on MSN11h
Micro Cap Soars Following Preliminary Data UpdateReal-time index price for PHLX Swiss Franc (XDS), along with buy or sell indicators, analysis, charts, historical performance ...
Recently, the research team led by Professor Zhang Zhongtao and Professor Yao Hongwei from the General Surgery Center at ...
Clinical Trials Arena on MSN1d
Surrozen drops hepatitis drug after Phase I flopSurrozen said despite SZN-043 demonstrating changes in liver function assays, there was not enough clinical benefit for ...
Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, ...
A recent study has unveiled the critical roles of two transcription factors, MAFB and CEBPA, in the development of ...
Surrozen is discontinuing its sole clinical-stage candidate and pivoting to its preclinical ophthalmology pipeline after the ...
ST316, a β-catenin/BCL9 antagonist, demonstrated safety, target engagement, and early antitumor activity in advanced solid ...
allAfrica.com on MSN7d
Expert Insights on Anticancer Potential of Ginger: A promising natural therapeutic strategyParticularly noteworthy among these compounds are 6-gingerol and 6-shogaol, which have been recognized for their potent ...
13d
Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback